Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma Market - Operating Income

Live News

On April 20, 2026, Biogen Inc. (NASDAQ: BIIB) announced a definitive agreement with China-based TJ Biopharma to acquire exclusive Greater China commercial rights and full global development rights to felzartamab, an anti-CD38 immunotherapy candidate for r/r MM, for total consideration of up to $850 million, tied to regulatory approval and sales performance milestones. As part of the agreement, Biogen will assume control of the already submitted biologics license application (BLA) to China’s Nati Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma MarketSome traders focus on short-term price movements, while others adopt long-term perspectives. Both approaches can benefit from real-time data, but their interpretation and application differ significantly.Diversifying the type of data analyzed can reduce exposure to blind spots. For instance, tracking both futures and energy markets alongside equities can provide a more complete picture of potential market catalysts.Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma MarketInvestors who track global indices alongside local markets often identify trends earlier than those who focus on one region. Observing cross-market movements can provide insight into potential ripple effects in equities, commodities, and currency pairs.

Key Highlights

First, global market data from GlobalData shows that anti-CD38 antibodies were used to treat 35.8% of all r/r MM patients in 2025, representing a $7.6 billion addressable market across the eight major global pharmaceutical markets (U.S., France, Germany, Italy, Spain, UK, Japan, China). Janssen Biotech’s first-in-class Darzalex (daratumumab) currently dominates the segment, holding 87.5% of global anti-CD38 prescription share and generating $7.1 billion in 2025 sales. Second, clinical trial data Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma MarketUnderstanding cross-border capital flows informs currency and equity exposure. International investment trends can shift rapidly, affecting asset prices and creating both risk and opportunity for globally diversified portfolios.Market behavior is often influenced by both short-term noise and long-term fundamentals. Differentiating between temporary volatility and meaningful trends is essential for maintaining a disciplined trading approach.Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma MarketSome traders find that integrating multiple markets improves decision-making. Observing correlations provides early warnings of potential shifts.

Expert Insights

From a strategic and financial perspective, Biogen’s felzartamab deal represents a low-risk, high-upside bet to diversify its revenue base and gain a foothold in China’s $31 billion oncology market, which is projected to grow at a 12% CAGR through 2030. The structure of the transaction, with the majority of the $850 million consideration tied to regulatory and sales milestones, limits Biogen’s downside exposure, as the company avoids upfront R&D costs for a therapy that has already completed late-stage trials and submitted its BLA to Chinese regulators. The domestic manufacturing designation is the most material competitive advantage for felzartamab, as China’s VBP programs have imposed average price cuts of 56% for imported oncology drugs over the past three years, while locally produced therapies are eligible for preferential VBP slots that allow for higher margin retention even at discounted price points. Even if Darzalex Faspro gains Chinese regulatory approval, felzartamab’s local production eligibility will allow Biogen to price the therapy 30% to 40% below imported Darzalex formulations, creating a strong value proposition for China’s public payers and cost-sensitive hospital systems. That said, there are material near-term risks to uptake. First, prescriber loyalty to Darzalex, which has 8 years of real-world clinical evidence in the Chinese market, will be difficult to displace, particularly as felzartamab’s Phase III clinical trial data has not yet been published in peer-reviewed journals, creating a trust gap among oncologists. Second, if Darzalex Faspro receives NMPA approval by 2027 as projected, it will eliminate felzartamab’s core convenience differentiator, forcing Biogen to rely exclusively on pricing and policy incentives to drive share. Consensus analyst estimates indicate that if felzartamab hits its 2029 market share target, it will generate roughly $67 million in annual Chinese revenue for Biogen, with potential upside to $120 million annually if the therapy is approved for earlier lines of MM treatment. Global rights to the therapy also create long-term optionality for Biogen to launch felzartamab in other emerging markets, where low-cost domestic manufacturing partnerships could be replicated to challenge Darzalex’s global dominance. For Biogen investors, the deal is broadly neutral in the near term, with potential to add 1.5% to 3% of top-line revenue by 2031 if commercial milestones are met. (Total word count: 1127) Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma MarketTracking order flow in real-time markets can offer early clues about impending price action. Observing how large participants enter and exit positions provides insight into supply-demand dynamics that may not be immediately visible through standard charts.The availability of real-time information has increased competition among market participants. Faster access to data can provide a temporary advantage.Biogen Inc. (BIIB) Secures Felzartamab Rights to Challenge Darzalex Dominance in China’s Multiple Myeloma MarketScenario modeling helps assess the impact of market shocks. Investors can plan strategies for both favorable and adverse conditions.